{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:59:20Z","timestamp":1790189960373,"version":"4.1.0"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"37","license":[{"start":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T00:00:00Z","timestamp":1757635200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,12]]},"abstract":"<jats:p>To comprehensively understand the disease burden of NASH-related liver cancer (NRLC) in China, we analyzed and evaluated the disease burden of NRLC in mainland China from 1990 to 2021 and predicted the trend in its health burden over the next 20 years. We characterized the burden of NRLC in China using the Global Burden of Disease (GBD) 2021 method and results based on incidence, prevalence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs). Joinpoint and age-period-cohort (APC) analysis methods were used to interpret the epidemiological characteristics and compare them with global prevalence trends. Moreover, the Bayesian age-period-cohort model was used to predict the incidence of mortality in different age groups over the next 20 years. From 1990 to 2021, the age-standardized incidence rates of males and females in China changed from 4.75 (95% confidence interval [CI]: 3.81\u20135.81) to 5.42 (95% CI: 4.18\u20136.85), and the mortality rate changed from 5.02 (95% CI: 4.01\u20136.14) to 5.06 (3.88, 6.42) per 100,000 people. The age-standardized DALY rate in China has decreased from 133.91 (95% CI: 107.69\u2013163.99) per 100,000 people in 1990 to 122.20 (95% CI: 94.14\u2013154.42) per 100,000 people in 2021. The average annual percentage changes (AAPCs) in the age-standardized incidence, prevalence, and mortality of NRLC in China were 0.44 (95% CI: 0.34\u20130.54), 1.00 (95% CI: 0.75\u20131.25), and 0.13 (95% CI: \u22120.36 to 0.61), respectively. Age, period, and cohort had different effects on the incidence and mortality. Personally, middle-aged and elderly men should pay more attention to the prevention of NRLC. Given the large population, growing SDI index, and aging trend in China, multiple prevention policies and popular education programs should be considered in the near future to minimize the burden of NRLC.<\/jats:p>","DOI":"10.1097\/md.0000000000044515","type":"journal-article","created":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T21:01:23Z","timestamp":1757970083000},"page":"e44515","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Burden and trends of nonalcoholic steatohepatitis-related liver cancer in China: A population-based observational study using GBD 2021 data"],"prefix":"10.1097","volume":"104","author":[{"given":"Meng-Xiang","family":"Xiang","sequence":"first","affiliation":[{"name":"Department of Peripheral Vascular Intervention, Changsha Central Hospital Affiliated to University of South China, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6108-6982","authenticated-orcid":false,"given":"Peng","family":"Yan","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang-Bei","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Peripheral Vascular Intervention, Changsha Central Hospital Affiliated to University of South China, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2478-3647","authenticated-orcid":false,"given":"Jie","family":"Tan","sequence":"additional","affiliation":[{"name":"Department of Interventional Vascular Surgery, Hunan Provincial People\u2019s Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260923","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","article-title":"Non-alcoholic fatty liver disease.","volume":"397","author":"Powell","year":"2021","journal-title":"Lancet"},{"key":"R2-20260923","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"R3-20260923","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: definition, risk factors and assessment.","volume":"33","author":"Wong","year":"2018","journal-title":"J Gastroenterol Hepatol"},{"key":"R4-20260923","doi-asserted-by":"crossref","first-page":"1510563","DOI":"10.3389\/fnut.2025.1510563","article-title":"Burden of NASH related liver cancer from 1990 to 2021 at the global, regional, and national levels.","volume":"12","author":"Li","year":"2025","journal-title":"Front Nutr"},{"key":"R5-20260923","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12072-021-10286-4","article-title":"Epidemiology and disease burden of non-alcoholic steatohepatitis in greater China: a systematic review.","volume":"16","author":"Zou","year":"2022","journal-title":"Hepatol Int"},{"key":"R6-20260923","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.jhep.2008.10.010","article-title":"Epidemiology of non-alcoholic fatty liver disease in China.","volume":"50","author":"Fan","year":"2009","journal-title":"J Hepatol"},{"key":"R7-20260923","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1002\/cam4.4551","article-title":"Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019.","volume":"11","author":"Liu","year":"2022","journal-title":"Cancer Med"},{"key":"R8-20260923","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/hep.29466","article-title":"Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.","volume":"67","author":"Estes","year":"2018","journal-title":"Hepatology"},{"key":"R9-20260923","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.3390\/cancers15225458","article-title":"From non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC): epidemiology, incidence, predictions, risk factors, and prevention.","volume":"15","author":"Motta","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R10-20260923","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/imj.14709","article-title":"Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management.","volume":"50","author":"Huang","year":"2020","journal-title":"Intern Med J"},{"key":"R11-20260923","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"R12-20260923","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1158\/1055-9965.EPI-20-1088","article-title":"Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study.","volume":"30","author":"Flores","year":"2021","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R13-20260923","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma.","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"R14-20260923","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/hep.30702","article-title":"Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis.","volume":"70","author":"Zhou","year":"2019","journal-title":"Hepatology"},{"key":"R15-20260923","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021.","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"R16-20260923","doi-asserted-by":"crossref","first-page":"1527328","DOI":"10.3389\/fpubh.2025.1527328","article-title":"Global burden and international disparities in NASH-associated liver cancer: mortality trends (1990-2021) and future projections to 2045.","volume":"13","author":"Nie","year":"2025","journal-title":"Front Public Health"},{"key":"R17-20260923","doi-asserted-by":"crossref","first-page":"e1378","DOI":"10.1016\/S2214-109X(25)00198-6","article-title":"Global, regional, and national prevalence of kidney failure with replacement therapy and associated aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.","volume":"13","year":"2025","journal-title":"Lancet Glob Health"},{"key":"R18-20260923","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3350\/cmh.2022.0239","article-title":"Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach.","volume":"28","author":"Le","year":"2022","journal-title":"Clin Mol Hepatol"},{"key":"R19-20260923","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"R20-20260923","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","article-title":"The trends in incidence of primary liver cancer caused by specific etiologies: results from the Global Burden of Disease Study 2016 and implications for liver cancer prevention.","volume":"70","author":"Liu","year":"2019","journal-title":"J Hepatol"},{"key":"R21-20260923","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"R22-20260923","doi-asserted-by":"crossref","first-page":"10977","DOI":"10.1038\/s41598-022-14701-0","article-title":"Lean non-alcoholic fatty liver disease (lean-NAFLD) and the development of metabolic syndrome: a retrospective study.","volume":"12","author":"Wang","year":"2022","journal-title":"Sci Rep"},{"key":"R23-20260923","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis.","volume":"20","author":"Le","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R24-20260923","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2471\/BLT.18.219469","article-title":"Countdown to 2030: eliminating hepatitis B disease, China.","volume":"97","author":"Liu","year":"2019","journal-title":"Bull World Health Organ"},{"key":"R25-20260923","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1097\/CM9.0000000000002331","article-title":"Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study.","volume":"135","author":"Cao","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R26-20260923","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13098-022-00976-w","article-title":"Estimates and trends of the global burden of NASH-related liver cancer attributable to high fasting plasma glucose in 1990-2019: analysis of data from the 2019 Global Burden of Disease Study.","volume":"15","author":"Li","year":"2023","journal-title":"Diabetol Metab Syndr"},{"key":"R27-20260923","first-page":"ehaf314","article-title":"Clinical staging to guide management of metabolic disorders and their sequelae: a European Atherosclerosis Society consensus statement.","author":"Romeo","year":"2025","journal-title":"Eur Heart J"},{"key":"R28-20260923","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN Inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial.","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"R29-20260923","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment.","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R30-20260923","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1097\/CM9.0000000000001888","article-title":"Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma.","volume":"134","author":"Rios","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"R31-20260923","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease.","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"R32-20260923","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1470-2045(22)00078-X","article-title":"Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.","volume":"23","author":"Tan","year":"2022","journal-title":"Lancet Oncol"},{"key":"R33-20260923","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cmet.2023.02.003","article-title":"The global burden of metabolic disease: data from 2000 to 2019.","volume":"35","author":"Chew","year":"2023","journal-title":"Cell Metab"},{"key":"R34-20260923","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","article-title":"Mechanisms and disease consequences of nonalcoholic fatty liver disease.","volume":"184","author":"Loomba","year":"2021","journal-title":"Cell"},{"key":"R35-20260923","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/obr.12106","article-title":"Programme and policy options for preventing obesity in China.","volume":"14","author":"Wang","year":"2013","journal-title":"Obes Rev"},{"key":"R36-20260923","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2468-1253(19)30342-5","article-title":"Liver diseases in the Asia-Pacific region: a lancet gastroenterology & hepatology commission.","volume":"5","author":"Sarin","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R37-20260923","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/JHC.S344559","article-title":"Hepatocellular carcinoma due to nonalcoholic fatty liver disease: current concepts and future challenges.","volume":"9","author":"Ahmad","year":"2022","journal-title":"J Hepatocell Carcinoma"},{"key":"R38-20260923","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s43587-024-00767-0","article-title":"Exploring the effects of estrogen deficiency and aging on organismal homeostasis during menopause.","volume":"4","author":"Camon","year":"2024","journal-title":"Nat Aging"},{"key":"R39-20260923","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/s41575-020-00381-6","article-title":"Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.","volume":"18","author":"Huang","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R40-20260923","doi-asserted-by":"crossref","first-page":"1047129","DOI":"10.3389\/fnut.2022.1047129","article-title":"Changes in the global, regional, and national burdens of NAFLD from 1990 to 2019: a systematic analysis of the global burden of disease study 2019.","volume":"9","author":"Wang","year":"2022","journal-title":"Front Nutr"},{"key":"R41-20260923","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/apt.15464","article-title":"Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study.","volume":"50","author":"Gawrieh","year":"2019","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044515","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:01:09Z","timestamp":1790186469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000044515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":41,"journal-issue":{"issue":"37","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044515","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,12]]},"assertion":[{"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}